T-614 is a novel disease modifying anti-rheumatic drug (DMARD) originally discovered by Toyama Chemical.
Toyama Chemical and Eisai are jointly developing T-614 under a co-development and licensing deal signed in 1998.
If approved, the drug will be co-promoted by Taisho Toyama Pharmaceutical and Eisai under a two-brand, two-channel scheme.